Prognosis
Emergent CEO Tells Lawmakers Firm Ready to Produce Shots in Days
- House panel says failures led to Covid-19 vaccine being wasted
- Emergent collected millions in fees amid problems, panel says
This article is for subscribers only.
Executives of embattled vaccine manufacturer Emergent BioSolutions Inc. defended the company at a U.S. House hearing on Wednesday, saying its Baltimore facility was stretched by the emergency production of shots.
A congressional probe into Emergent has found that the contract manufacturer failed to address deficiencies in vaccine production at its facilities despite warnings following a series of inspections in 2020.